Scarica l'app Stockscreener
660.09
1.07%
7.1775
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Wells Fargo & Company Issues Positive Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - MarketBeat
Cantor Fitzgerald Boosts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $740.00 - MarketBeat
Regeneron (REGN) Margin Compression Reinforces Cautious Community Narratives Heading Into Earnings Season - Yahoo Finance
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $865.00 at Guggenheim - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, Bank of America Analyst Says - MarketBeat
Can Regeneron Pharmaceuticals Inc. stock maintain operating marginsTrade Exit Report & Verified Swing Trading Watchlists - newser.com
Why Regeneron Pharmaceuticals Inc. stock is considered a top pickCPI Data & Daily Oversold Bounce Ideas - newser.com
CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025 - GlobeNewswire Inc.
Regeneron (REGN) Margin Dip Underscores Market Caution Despite Strong Relative Valuation - simplywall.st
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Evergreen Wealth Management LLC - MarketBeat
Why Regeneron Pharmaceuticals Inc. (RGO) stock is listed among top recommendations - newser.com
Using fundamentals and technicals on Regeneron Pharmaceuticals Inc.Profit Target & Risk Controlled Stock Alerts - newser.com
Wealthfront Advisers LLC Sells 1,560 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by AlphaQuest LLC - MarketBeat
Why millennials buy Regeneron Pharmaceuticals Inc. (RGO) stockJuly 2025 PostEarnings & AI Driven Stock Price Forecasts - newser.com
Why Regeneron Pharmaceuticals Inc. (RGO) stock is a strong buy callWeekly Trade Report & Free Safe Capital Growth Stock Tips - newser.com
News impact scoring models applied to Regeneron Pharmaceuticals Inc.Fed Meeting & Daily Oversold Bounce Ideas - newser.com
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to Issue $0.88 Quarterly Dividend - MarketBeat
In a $1B+ deal, Modex joins with Regeneron to develop antibodies - BioWorld MedTech
Regeneron receives another CRL for its Eylea 8 mg - Ophthalmology Times
Regeneron's Portfolio Still Supports a Narrow Moat Despite Competitive Threats to Eylea - Morningstar
REGN Receives Analyst Rating Boost with New Price Target | REGN Stock News - GuruFocus
Regeneron Pharmaceuticals (REGN) Sees Revised Price Target by RB - GuruFocus
Regeneron Q3 Earnings Review: This Is The Start Of A Dupixent Driven Comeback (REGN) - Seeking Alpha
Regeneron’s Aflibercept Study Sheds Light on Retinal Vasculitis Incidence - TipRanks
Regeneron Adds Fuel to Hot Healthcare Trade. Which Stocks Could Follow it Higher? - Barron's
Market Starting To Embrace The 'New' Regeneron (NASDAQ:REGN) - Seeking Alpha
Regeneron pledges more than $1B biobucks for ModeX multispecific antibodies - Fierce Biotech
Regeneron Pharmaceuticals (NASDAQ:REGN) Shares Gap Up Following Earnings Beat - MarketBeat
Wells Fargo Raises Regeneron (REGN) Price Target Amidst Equal-We - GuruFocus
Regeneron teams up with Gary Nabel’s ModeX on multispecifics - Endpoints News
Cantor Fitzgerald Boosts Price Target for Regeneron Pharmaceuticals (REGN) | REGN Stock News - GuruFocus
Regeneron Pharmaceuticals (NASDAQ:REGN) Announces Earnings Results, Beats Estimates By $2.10 EPS - MarketBeat
Guggenheim Raises Regeneron Pharmaceuticals (REGN) Price Target to $865 | REGN Stock News - GuruFocus
Regeneron Partners With ModeX Therapeutics To Discover And Develop Multispecific Antibodies - Nasdaq
FDA Formally Rejects Regeneron’s Eylea HD Over Manufacturing Issues - BioSpace
FDA rejects Regeneron’s pre-filled Eylea HD syringes amid filling facility woes - Yahoo Finance
Regeneron Pharmaceuticals (REGN) Analyst Rating Update: Price Ta - GuruFocus
RBC Raises Price Target on Regeneron Pharmaceuticals to $708 From $704, Keeps Sector Perform Rating - MarketScreener
Opko Health’s ModeX enters license, collab agreement with Regeneron - TipRanks
FDA rejects Regeneron’s Eylea HD amid filling facility woes - Pharmaceutical Technology
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q3 2025 Earnings Call Transcript - Insider Monkey
OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications - Yahoo Finance
What data driven models say about Regeneron Pharmaceuticals Inc.’s futureJuly 2025 Rallies & Real-Time Volume Analysis - newser.com
Morgan Stanley Adjusts Price Target on Regeneron Pharmaceuticals to $767 From $756, Maintains Overweight Rating - MarketScreener
BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $725 From $640, Maintains Outperform Rating - MarketScreener
Evaluating Regeneron After Recent Pipeline News and Sharp 13% Stock Surge - simplywall.st
Citigroup Adjusts Price Target on Regeneron Pharmaceuticals to $700 From $660, Maintains Buy Rating - MarketScreener
Baird Adjusts Price Target on Regeneron Pharmaceuticals to $630 From $587, Maintains Neutral Rating - MarketScreener
General American Investors Co. Inc. Sells 5,000 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
TD Cowen Adjusts Price Target on Regeneron Pharmaceuticals to $800 From $780, Maintains Buy Rating - MarketScreener
Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $788 From $785, Maintains Buy Rating - MarketScreener
Leerink Partners Adjusts Price Target on Regeneron Pharmaceuticals to $710 From $645, Maintains Outperform Rating - MarketScreener
Raymond James Adjusts Price Target on Regeneron Pharmaceuticals to $723 From $673, Maintains Outperform Rating - MarketScreener
Cantor Fitzgerald Adjusts Price Target on Regeneron Pharmaceuticals to $740 From $658, Maintains Overweight Rating - MarketScreener
JPMorgan Adjusts Price Target on Regeneron Pharmaceuticals to $850 From $800, Maintains Overweight Rating - MarketScreener
Novartis’ Big Buy, Q3 Earnings, Regeneron’s Dropped Cell Therapy, More - BioSpace
Heatmap analysis for Regeneron Pharmaceuticals Inc. and competitorsBull Run & Stock Timing and Entry Methods - newser.com
Teacher Retirement System of Texas Cuts Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
OVERSEA CHINESE BANKING Corp Ltd Cuts Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals Faces Financial Risks Amid Tariff and Trade Challenges - TipRanks
Decoding Regeneron Pharmaceuticals Inc (REGN): A Strategic SWOT Insight - GuruFocus
Regeneron Pharmaceuticals Reports Q3 2025 Financial Results - TipRanks
Regeneron Earnings Call: Strong Growth Amid Challenges - TipRanks
Regeneron's Earnings Took A Big Tax Hit, And Still Pounded Forecasts - Investor's Business Daily
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Regeneron (REGN) Q3 2025 Earnings Call Transcript - The Motley Fool
Big Names In Health Care Diverge As Market Stumbles - Finimize
Tranche Update on Regeneron Pharmaceuticals, Inc.'s Equity Buyback Plan announced on February 4, 2025. - MarketScreener
JPMorgan Raises Price Target on Regeneron Pharmaceuticals to $850 From $800 - MarketScreener
Pharma Boom: Regeneron’s Latest Innovations - StocksToTrade
REGN Stock Up on Q3 Earnings Beat, Eylea HD Sales Increase - Yahoo Finance
FDA rebuff puts new dent in Regeneron's bid to crank up Eylea HD rollout - FirstWord Pharma
7.59%
13.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):